natgillin/translations-raw huggingface dataset:
is a nucleofugic group or an optionally substituted aliphatic, aromatic, or heteroaromatic group; and 
R? je nukleofugalna grupa ili izborno supstituirana alifatična, aromatična ili heteroaromatična grupa; i
To the filtrate was added maleic acid (17.4 g) and after stirring a precipitate was produced. 
Na filtrat se doda maleinska kiselina (17,4 g) i nakon miješanja proizvodi se talog.
Use of (a) a corticosteroid as defined in any one of claims 1 and 3 to 6 for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 10 or 11. 
Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (b) antagonistom muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11. t>&
The generation of oxygen radicals in postischemic tissues appears to overcome the capacity of endogenous antioxidants such as superoxide dismutase (SOD), catalase, glutathione to protect endothelial and parenchymal cells. 
Čini se da stvaranje kisikovih radikala u postishemijskim tkivima prelazi mogućnost endogenih antioksidanata, kao što je superoksidna dismutaza (SOD), katalaza, glutationa da zaštiti endotelne i parenkimalne stanice.
A compound as claimed in claim 1, 2 and 3 wherein said compound is compound No.1a, compound No.30, compound No.39 and compound No.50. 
Spoj prema zahtjevu 1, 2 i 3 naznačen time da navedeni spoj je spoj br.1a, spoj br.30, spoj br.39 i spoj br.50. [image]
The pharmaceutical composition according to claim 1, comprising 175.00 mg of Capecitabine, 5.00 mg of Hypromellose, 87.50 mg of Crospovidone, 82.50 mg of Mannitol, 115.16 mg of Microcrystalline Cellulose, 10.37 mg of Magnesium Stearate, 21.76 mag of Aspartame, 4.50 mg of Saccharin Sodium, 11.00 mg of Vanillin, 2.06 mg of Bittermasking Blend and 4.15 mg of Strawberry Flavor. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da sadrži 175,00 mg kapecitabina, 5,00 mg hipromeloze, 87,50 krospovidona, 82,50 mg manitola, 115,16 mg mikrokristalinične celuloze, 10,37 mg magnezij stearata, 21,76 mg aspartama, 4,50 mg natrij saharina, 11,00 mg vanilije, 2,06 mg smjese za maskiranje gorčine i 4,15 mg arome jagode.
A polymorph according to claim 5 characterised in that it provides an XRPD pattern comprising peaks substantially as set out in Table 2 Table 2 
Polimorf u skladu s patentnim zahtjevom 5, naznačen time što daje XRPD uzorak koji sadrži signale kao što su u osnovi iznijeti u Tablici 2 Tablica 2 [image]
The preventive or therapeutic agent for a proliferative disease according to claim 47, wherein the cancer is a cancer depending on the Ras-MAPK signaling pathway. 
Sredstvo za sprječavanje ili liječenje proliferativne bolesti u skladu s patentnim zahtjevom 46, naznačeno time što rak je rak koji ovisi o signalnom putu Ras-MAPK.
compressing the final blend into tablet cores; preparing a coating suspension; coating the tablet cores with the coating suspension to a weight gain of about 2-4 % to produce film-coated tablets. 
Postupak u skladu sa zahtjevom 8, naznačen time, da nadalje sadrži h. komprimiranje konačne mješavine u tabletne jezgre; i. pripremu suspenzije za oblaganje; j. oblaganje tabletnih jezgri suspenzijom za oblaganje do dobivanja na težini od oko 2-4% da bi se pripremilo film-obložene tablete.
Ammunition hoist according to claim 1, wherein said movement system (5) is an oleodynamic system. 
Sustav za podizanje municije u skladu s patentnim zahtjevom 1, naznačen time što je navedeni sustav za pomicanje (5) hidraulički sustav.
In one or more embodiments, the composition comprises 3 to 50% by weight of at least one component (a), 40 to 90% by weight of at least one component (b), 1 to 10% by weight of at least one component (c), 0.5 to 5% by weight of at least one component (d), and less than or equal to 20% by weight of water. 
| Sastav prema patentnom zahtjevu 1, koji sadrži 3 do 50, posebno 5 do 45, poželjno 10 do 40 % po masi barem jedne komponente (a) 40 do 90, posebno 50 do 85, poželjno 55 do 80 % po masi barem jedne komponente (b) 1 do 10, posebno 2 do $, poželjno 3 do 6 % po masi barem jedne komponente (c) 0,5 do 5, posebno 2 do 8, poželjno 3 do 6 % po masi barem jedne komponente (d) manje od ili jednako 20 % po masi vode.
a joint, where a side of the joint is provided with an inlet, another side of the joint is provided with a tube insertion cavity, and an inner end of the tube insertion cavity is connected to the inlet; 
konektor (1), gdje jedna strana konektora (1) ima ulaz, dok druga strana konektora (1) ima šupljinu za cijevi, gdje je unutrašnjost šupljine za cijevi spojena s navedenim ulazom;
A kit comprising a container containing a pharmaceutical composition containing the peptide according to any one of claims 1 to 4 or the activated cytotoxic T lymphocyte according to claim 11, in solution or in lyophilized form. 
Kutije koja sadrži farmaceutski sastav koji se sastoji od peptida u skladu s bilo kojim zahtjevom 1 - 4, nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, stanice u skladu s patentnim zahtjevom 7 ili 8, ili aktiviranog citotoksičnog T-limfocita u skladu s patentnim zahtjevom 11, u otopini ili liofiliziranom obliku; i
In more specific embodiments of formula (VIII), x is 11, and the invention provides a GLA compound having the following structure (IX): 
O 7. GLA spoj u skladu s patentnim zahtjevom 6, naznačen time što je x 11, a GLA spoj ima sljedeću strukturu (IX):
or one of R6, R6a, R7, and R7a together with one of R8, R8a, R9 and R9a form an alkylene bridge, while the remaining R6, R6a, R7, R7a, R8, R8a, R9, and R9a are each independently selected from hydrogen or C1-C3alkyl; 
je vodik ili C1-C3alkil; i svaki R12 je neovisno odabran od vodika ili C1-C6alkila; međutim uz uvjet da R2ne može biti pirazinil, piridinonil, pirolidinonil ili imidazolil; njegov stereoizomer, enantiomer ili tautomer, njegova farmaceutski prihvatljiva sol, ili njegov farmaceutski sastav.
Although not shown in FIG. 1, the 2′S isomer of TPI 285, as shown above, is also contemplated. 
Iako nije prikazan na slici 1, 2'S izomer TPI 285, kao što je pokazano gore, se također razmatra.
Cy1 is a monocyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; 
je vodik, halogen, cijano, supstituiran ili nesupstituiran alkil, supstituiran ili nesupstituiran alkinil, supstituiran ili nesupstituiran heterociklil, supstituiran ili nesupstituiran aril, ili supstituiran ili nesupstituiran heteroaril;
C1-7 alkyl optionally substituted by fluoro, 
(3) Ci; alkil opcijski supstituiran s fluorom,
(viii) endothelin antagonist or a pharmaceutically acceptable salt thereof, 
(viii) antagonist endotelina ili njegova farmaceutski prihvatljiva sol,
After stirring the reaction at -78 °C for 30 minutes 2[NN-Bis(trifluromethylsufonyl)amine]-5-chloropyridine (1.4 g, 3.6 mmol) was added. 
Nakon miješanja reakcije na -78* C tijekom 30 minuta, dodan je 2[NN-bis(trifluorometilsulfonil)amin]-5-kloropiridin (1.4 g, 3.6 mmol).
In another embodiment, the compound is of the formula (VI), where D is a moiety of the formula: 
3. Spoj patentnog zahtjeva 1 gdje je D struktura formule:
at least one substitution or addition of a hydrophilic amino acid in a hydrophobic domain of the F protein extracellular domain. 
(ili) najmanje jednu supstituciju ili adiciju hidrofilne aminokiseline u hidrofobnoj domeni izvanstanične domene F proteina.
The method according to any of the preceding claims wherein the feedstock is wheat straw. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, pri čemu se celulozni materijal podvrgava silama razdvajanja u reaktoru pod tlakom.
This is a break-through for the industry of surface materials. 
To je prelomna točka za industriju površinskih materijala.
a light chain variable domain having the amino acid sequence of SEQ ID NO: 89; 
(A) varijabilnu domenu lakog lanca koja ima aminokiselinski slijed SEQ ID NO: 89;
A compound, pharmaceutically acceptable salt thereof or composition according to claim 5, for use in treatment of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Spoj, njegova farmaceutski prihvatljiva sol ili smjesa prema zahtjevu 5, za uporabu u liječenju bolesti ili stanja izabranih između; emocionalna nestabilnost; pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropatska bol; bol posredovana simpatikusom; bol povezana s disfunkcijom probavnog sustava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.
targeting a genomic locus of interest in a pluripotent rat cell according to the method of any one of claims 1-21 to form a genetically modified pluripotent rat cell, wherein the insert nucleic acid comprises a human nucleic acid; and introducing the genetically modified pluripotent rat cell into a host rat embryo. 
(a) usmjeravanje genomskog lokusa od interesa u pluripotentnu štakorsku stanicu sukladno postupku prema bilo kojem od patentnih zahtjeva 1-20 da bi se oblikovala genetski modificirana pluripotentna štakorska stanica, pri čemu umetak nukleinske kiseline sadrži humanu nukleinsku kiselinu; i (b) uvođenje genetski modificirane pluripotentne stanice štakora u embrij domaćina štakora.
determining (406) a first thread priority of the first thread based on a first task priority of the first task; 
određivanje (406) prioriteta prve niti temeljem prioriteta prve zadaće;
The method of item 6, wherein the subject exhibits at least a 25% increase in T1 lesion load over a period of one year prior to the administration of the compound. 
Spoj ili sol za uporabu prema zahtjevu 1, gdje subjekt pokazuje barem 25% porasta T1 lezija u vremenu od jedne godine prije primjene spoja.
whole cell pertussis components, and/or hepatitis B surface antigen; 
tetanusni toksoid (TT), difterijski toksoid (DT), te cjelostanične komponente pertusisa i/ili površinski antigen virusa hepatitisa B;
at least 90 mole percent residues of ethylene glycol, based on the total amount of diol residues in the one or more polyethylene terephthalate homopolymers or copolymers comprising 100 mole percent, and 
(ii) najmanje 90 molarnih postotaka ostataka etilen-glikola, prema ukupnoj količini diolnih ostataka u jednom ili više homopolimera ili kopolimera polietilen-tereftalata koji sadrže 100 molarnih postotaka.
y is an amino acid other than Cys, and wherein said cyclic peptide consists of at least 16 and of at most 25 amino acids and comprises the amino acid stretch Asp-Xxx1-Xxx4-Arg-Arg-Cys-Xxx3-Asn-Asp-Pro-Lys (SEQ ID NO. 
€) yje aminokiselina koja nije Cys, 1 gdje navedeni ciklički peptid se sastoji od najmanje 16, a najviše 25 aminokiselina i ima aminokiselinski slijed
The fuel element was provided with a 0.040 in (1.02 mm) longitudinal passageway. 
Gorivi element je osiguran sa uzdužnim prolazom od 1.02 mm.
The present invention also provides a method for preventing, treating or ameliorating an RORYt mediated inflammatory syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound of Formula I or a form, composition or medicament thereof. 
Spoj prema bilo kojim zahtjevima 1 do 13 za upotrebu u postupku za liječenje subjekta koji pati od ili kome je dijagonosticiran RORyt posredovani upalni sindrom, poremećaj ili bolest; HR P20190900 T1
said ceftriaxone sodium in an amount of 0.125 g, calculated as ceftriaxone free acid, 
(a) spomenuti ceftriakson natrij u količini od 0.125 g, preračunato kao ceftriaksonska slobodna kiselina,
The combination according to any one of claims 1 to 4, wherein the compound of Formula I is a compound selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, naznačen time što je to spoj izabran iz grupe koju čine:
In a preferred embodiment, the antibody or binding molecule of the invention binds L1 with an affinity (KD) of at least 10−8, preferably of at least 10−9, more preferably of at least 10−10 or 10−11. 
Vežuća molekula koja se može vezati na L1 u skladu s patentnim zahtjevom 1, naznačena time što se vežuća molekula veže na LI s afinitetom (KD) od najmanje 107" M.
Another aspect of the invention is directed to methods for assessing a patient's likelihood of favorably responding to a weight-loss pharmaceutical agent. The methods include: (a) measuring a level of TRL V6 in at least two in vitro samples from the patient, at least one taken in conjunction with administration of the weight-loss pharmaceutical agent to the patient; (b) electronically identifying whether there is a reduction in TRL V6 level associated with the weight loss agent; and (c) assessing a patient's likelihood of favorably responding to the weight loss pharmaceutical agent based on the identifying step. 
Postupak procjenjivanja vjerojatnosti da pacijent povoljno reagira na farmaceutsko sredstvo za smanjivanje tjelesne težine, naznačen time što se sastoji u: mjerenju koncentracije TRL V6 kod najmanje dva in vitro uzorka iz pacijenta, gdje se najmanje jedan uzima povezano s primjenom farmaceutskog sredstva za smanjivanje tjelesne težine na pacijentu; HR P20110840 T1 elektronskom procjenjivanju je li došlo do smanjivanja razine TRL V6 povezanog s farmaceutskim sredstvom za smjanjivanje tjelesne težine; i procjenjivanju vjerojatnosti da pacijent povoljno reagira na farmaceutsko sredstvo za smjanjivanje tjelesne težine na osnovu koraka elektronskog procjenjivanja.
The antibody for use of claim 13 the conjugate for use of claim 13 or the pharmaceutical composition of claim 12 for use in a method of treating or preventing a tumor or cancer disease or disorder . 
Antitijelo za primjenu iz patentnog zahtjeva 13 konjugat za primjenu iz patentnog zahtjeva 13 ili farmaceutska kompozicija iz patentnog zahtjeva 12 za primjenu u metodi liječenja 1li prevencije tumorske ili kancerogene bolesti ili poremećaja.
A winder unit (1) in accordance with any preceding claim, wherein, in set up, the cutting wire passes through the bonding material at a position proximate a corner of the glazing panel. 
Jedinica za namatanje, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što, u radnim uvjetima, žica za rezanje prolazi kroz materijal za vezanje na položaju koji je u blizini ugla prozorskog panela.
a BCH decoder (r713-L1)configured to BCH-decode the LDPC-decoded Layer 1 signaling data and de-punctured LDPC parity bit, characterized in that the receiver is configured to process Layer 1 signaling data having a notch start information field indicating a start position of an associated notch band, wherein the number of bits used for the notch start information field varies with a guard interval value.. 
BCH dekoder (1715-L1) konfiguriran za BCH dekodiranje LDPC dekodiranog signalnog podatka razine 1 i sabijenog paritetnog bita, karakteriziran na način da signalni podatak razine 1 uključuje polje s informacijom početka obilježja koje ukazuje na početni položaj pridružene širine obilježja, pri čemu broj bitova korišten za polje s informacijom početka obilježja varira s vrijednosti intervala čuvara.
Three 14 mL milk samples were prepared in duplicate in 20 mL SPME (solid phase micro-extraction) vials (flat bottom (23mm x 75mm) headspace vial with PTFE lined silicone closure (cat. no. 27199 and 27300) ex Supelco®) in a glove box under a carbon dioxide atmosphere and sealed tight. Samples A and C: Milk without addition 
Tri uzorka mlijeka od 14 mL se pripreme u duplikatu u 20mL SPME (solid phase micro-extraction - mikroekstrakcija na čvrstoj fazi) bočicama (ravno dno (23mm x 75mm) gornji prostor bočice s PTFE obloženim silikonskim zatvaračem (kat. br. 27199 i 27300) iz Supelco*) u pristajućoj kutiji pod atmosferom ugljik dioksida i hermetički zatvore.
is selected from hydrogen, alkyl (optionally substituted at one or more positions by halogen, hydroxy or alkoxy), aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl is each optionally substituted at one or more positions by halogen, aminosulfonyl, lower alkyl-aminosulfonyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), hydroxy or alkoxy (optionally substituted at one or more positions by halogen or hydroxy); 
je izabran iz skupine koju čine vodik, alkil (po izboru supstituiran u jednom ili više položaja s halogenom, hidroksi ili alkoksi), aril, C3-C12 cikloalkil ili heterociklil, pri čemu je svaki od aril, C3-C12 cikloalkil ili heterociklil po izboru supstituiran u jednom ili u više položaja s halogenom, aminosulfonil, nižim alkil-aminosulfonil, alkil (po izboru supstitiranim u jednom ili više položaja s halogenom, hidroksi ili nižim alkoksi), hidroksi ili alkoksi (po izboru supstituiranim u u jednom ili više položaja s halogenom ili hidroksi);
One or more oligomers of lactic acid for use according to any of the preceding claims, wherein the one or more oligomers of lactic acid is comprised in a composition the form of a tampon, vagitorium, vaginal aerosol, vaginal cup, vaginal gel, vaginal insert, vaginal patch, vaginal ring, vaginal sponge, vaginal soppository, vaginal cream, vaginal emulsion, vaginal foam, vaginal lotion, vaginal ointment, vaginal powder; vaginal shampoo, vaginal solution, vaginal spray, vaginal suspension, vaginal tablet, vaginal rod, vaginal shaum, vaginal disc, semipermeable packaging and any combination thereof. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline sadržan u pripravku u obliku tampona, vagitorija, vaginalnog aerosola, vaginalne šalice, vaginalnog gela, vaginalnog inserta, vaginalnog flastera, vaginalnog prstena, vaginalne spužve, vaginalnog čepića, vaginalne kreme, vaginalne emulzije, vaginalne pjene, vaginalnog losiona, vaginalne pomasti, vaginalnog pudra; vaginalnog šampona, vaginalne otopine, vaginalnog spreja, vaginalne suspenzije, vaginalne tablete, vaginalnog štapića, vaginalnog šauma, vaginalnog diska, semipropusnog materijala ili bilo koje kombinacije istih. HR P20140559 T1
Examples of base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol. 
Primjeri materijala za podloge koje se upotrerbljava za supozitorije, uključuju, primjerice, kakao-maslac, emulgirani kakao-maslac, laurinski lipid, te Witepsol.
a plurality of longitudinally extending channels defined by longitudinally extending ribs formed on the outer surface of the elongate structure, the channels being arranged and configured to transport a liquid along the elongate wick; and 
veliki broj uzdužno prostirućih kanala (84) koji su definirani uzdužno prostirućim rebrima (82), koja su oblikovana na vanjskoj površini izdužene strukture, pri čemu su kanali raspoređeni i konfigurirani za prijenos tekućine duž izduženog fitilja; i
A method according to claim 15 wherein the solvent for the preparation of the solution of the alkylating agent is acetonitrile. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što je otopina za pripremu otopine alkalnog sredstva acetonitril.
R1- represents an anion associated with the positive charge of the N atom; and 
R1 predstavlja anion povezan s pozitivnim nabojem na N atomu; i
substantially removing the alcohol by-products from the second mixture; and reacting the compound of the Formula V with tosylchloride in situ to form a sulphonate ester in the presence of a suitable base and toluene to form the compound of the Formula II. 
(d) većinskog uklanjanja alkoholnih nus-produkata iz druge mješavine, i (6) reakcije spoja prema formuli V sa pogodnim sredstvom za sulfoniranje in situ koji tvore sulfonatni ester u prisutnosti pogodne baze i toluena koji tvore spoj prema formuli Ila.
A process for preparing a mineral composition containing a mixed solid phase of calcium and magnesium carbonates, comprising: 
Postupak priprave mineralne mješavine na bazi miješane čvrste faze kalcijevih 1 magnezijevih karbonata, naznačen time što se sastoji od -i)
The method of claim 4, wherein said cancer is a lung tumor, a breast tumor, a kidney tumor, an eye tumor, a liver tumor, a colorectal tumor, a tumor of an urinary organ, or a metastatic cancer from a breast tumor, a lung tumor, a melanoma, or a brain tumor. 
Konjugat ili pripravak za uporabu kako je opisano u zahtjevu 18, naznačen time da navedeni karcinom je tumor pluća, tumor dojke, tumor bubrega, očni tumor, tumor jetre, tumor debelog crijeva, ili tumor mokraćnog organa.
The crude product was purified by flash chromatography on silica using a gradient of ethyl acetate in heptane. 
Kruti produkt se potom pročišćava sa brzom kromatografijom na silika gelu, uz korištenje gradijenta etil acetata u heptanu.
The kit of any one of claims 6 to 8, wherein the second composition further comprises carbidopa, benserazide, entacapone, tolcapone, or a combination thereof. 
Komplet iz bilo kojeg od patentnih zahtjeva 6 do 8, naznačen time, da drugi pripravak nadalje sadrži karbidopu, benserazid, entakapon, tolkapon ili njihovu kombinaciju.
One aspect of the invention provides a method for reducing IL-6 and/or VCAM-1 in a subject comprising administering to the subject in need thereof, a therapeutically effective amount of at least one compound of Formula I: 
PATENTNI ZAHTJEVI 1. = Farmaceutski sastav, naznačen time, da se upotrebljava u smanjivanju IL-6 za liječenje raka kod pojedinca, pri čemu sastav obuhvaća terapeutski učinkovitu količinu najmanje jednog spoja formule I:
In order to restore the normal shape 
Da se rekonstruira normalni oblik 16
The compound of any one of claims 1, 6, 7, 8, or 9, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein at least one of R3, R1, R5, or R6 is optionally substituted -(C1-C8 alkylene)x-hetero C3-C10 cycloalkyl, wherein the hetero C3-C10 cycloalkyl does not include unsubstituted N-morpholinyl, N-piperidyl, or N-thiomorpholinyl. 
Spoj prema bilo kojem zahtjevu 1, 6, 7, 8 ili 9, ili stereoizomer ili njegova farmaceutski prihvatljiva sol, naznačen time da najmanje jedan od R*, R", R? ili R* je proizvoljno supstituiran -(C;-Ca alkilen),-hetero C3-C;g cikloalkil, pri čemu hetero Ca-Ciy cikloalkil ne uključuje nesupstituirani N-morfolinil, N- piperidil ili N-tiomorfolinil.
for each coefficient located before the last non-zero coefficient, an information item is entropically encoded in order to indicate whether or not the coefficient is zero, 
broj koeficijenata, od prvog nenultog koeficijenta do zadnjeg nenultog koeficijenta, uključujući prvi i zadnji nenulti koeficijent, je veći od četiri;